摘要
外周T细胞淋巴瘤（PTCL）是一组高度异质且预后极差的恶性肿瘤，基因异常和分子生物学改变是其发生、发展的重要因素。目前，PTCL的治疗仍然借鉴侵袭性B细胞淋巴瘤的化疗方案，但是疗效并不显著。表观遗传学作为一门涉及基因表达调控的新兴学科，为PTCL的发生、发展机制的研究与临床诊断治疗提供了新的思路。同时，针对PTCL的新型表观遗传学靶向药物的研发及新药联合应用方案的研究亦在进行中。因此，表观遗传学调控为PTCL的诊断及治疗提供了新的治疗切入点。笔者拟就PTCL的表观遗传学机制研究及相关靶向新药的应用前景进行综述。
Peripheral T cell lymphoma （PTCL） is a group of heterogeneous lymphomas with very poor prognosis. Abnormal genes and molecular biology alterations are significant factors in the occurrence and development of PTCL. Currently, therapies of PTCL, based on chemotherapy regimens for aggressive B cell lymphomas, have resulted in insufficient outcomes. As a novel subject related to gene expression and regulation, epigenetics provides an innovative thought for studying on pathogenesis, clinical diagnosis and therapy of PTCL. Meanwhile, numerous novel epigenetie target-drugs and combinations have been developed continually. Therefore, epigenetic regulation offers a new breakthrough for diagnosis and therapy of PTCL. In this review, the mechanism of epigenetic study and application prospect of new epigenetic target-drugs therapies for PTCL are summarized.
出处
《国际输血及血液学杂志》
CAS
2016年第6期517-520,共4页
International Journal of Blood Transfusion and Hematology
基金
山西省卫生厅科技攻关项目（2011044）
